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e.2011.10Abstract Background: A hypercoagulable stable has been documented in patients with
b-thalassemia. However, the underlying mechanisms are multifactorial. The role of soluble protein
C endothelial receptor in hemostatic derangement in these patients has not been investigated.
Design and methods: Plasma soluble EPCR and markers of coagulation have been analyzed in 15
splenectomized patients (group I) and 15 non-splenectomized patients (group II).
Results: We showed signiﬁcantly higher levels of sEPCR in patients versus the control and in group
I more than group II. Levels of sEPCR positively correlated with total leukocytic and platelet
counts. No correlation could be established between sEPCR and either age or sex.
Conclusion: The data indicate that high sEPCR levels could be implicated in the hemostatic
derangement and endothelial cell dysfunction in patients with b-thalassemia.
ª 2011 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Thalassemia represents the most common hereditary hemolytic
anemia which results from partial or complete lack of synthesis
of one of the a or b globin chain of Hb.1 b-Thalassemia is the
most common type in Egypt with a carrier rate ranging from
5.3% to >9% and a gene frequency of 0.03%.2.com (M. Elgammal).
xandria University Faculty of
g by Elsevier
y Faculty of Medicine. Production
.007Patients with b-thalassemia exhibit thrombotic complica-
tions with several published series demonstrating the presence
of both arterial and venous thrombosis.3
The pathogenesis of this hypercoagulability is multifactorial
implicating reactive oxygen species in the oxidized red cell
membrane lipids4 and loss of their organization,5 alterations
in markers of coagulation activation and natural anticoagulant
proteins,6 thrombophilic DNA mutations,7 endothelial,
monocytic and granulocyte activation.8 Endothelial protein C
receptor (EPCR) is a type I transmembrane protein, mainly ex-
pressed on the luminal endothelial cell surface of large blood
vessels.9 It plays an anticoagulant role in hemostasis by binding
to protein C with high afﬁnity and it increases by more than 10
fold the generation of the activated protein C (APC). It also
binds to factor VIIa and inhibits its coagulant activity.10,11and hosting by Elsevier B.V. All rights reserved.
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thrombin, vascular injury or regulated proteolytic cleavage
by metalloproteinases.12,13
2. Aim of the work
The aim of the present work was to estimate the plasma levels
of sEPCR in patients with b-thalassemia.
3. Design and methods
Thirty adult patients with established b-thalassemia major
were enrolled in this study, (15 splenectomized: group I and
15 non-splenectomized: group II) they were recruited from
the Hematology Department of the Medical Research Insti-
tute. Thirty normal healthy individuals with matched age
and sex served as control. They had no any history of venous
thrombosis, renal dysfunction or smoking.
All patients and controls gave informed consent for enroll-
ment in accordance with the Declaration of Helsinki and the
study was approved by the Medical Research Institute Ethical
Committee.4. Methods
All patients were thoroughly examined. Laboratory investiga-
tions included CBC using automated cell counter14 (SysmexTable 1 Hematological parameters in patients compared to contro
Cases
Hb (g/dl) Mean ± SD 7.6 ± 1.1
Min–Max 5.7–10.8
Median 7.5
RBC (·1012 L1) Mean ± SD 2.9 ± 0.6
Min–Max 1.9–4.6
Median 2.9
MCV (Fl) Mean ± SD 67.9 ± 6
Min–Max 50.3–79.2
Median 69.9
WBC (·109 L1) Mean ± SD 9.8 ± 2.9
Min–Max 5.3–19.2
Median 9.4
Platelets (·109 L1) Mean ± SD 428.1 ±
Min–Max 141.0–79
Median 450.0
MPV (Fl) Mean ± SD 9.2 ± 1.2
Min–Max 7.1–11.4
Median 9.4
Normoblasts/100WBCs Mean ± SD 21.9 ± 3
Min–Max 4.0–222.0
Median 12.5
Absolute reticulocytic count Mean ± SD 130,500 ±
Min–Max 47,500–3
Median 130,500
# P value based on Mann–Whitney test.
* P< 0.05 (signiﬁcant).XT-1800i), PT and INR by quick one stage method using cal-
cium thromboplastin, PTT with Kaolin (KCCT) using
pathrombin,15 D-dimer by semi-quantitative latex agglutina-
tion kit (DiALAB, Austria)15 and estimation of sEPCR by
ELISA (Stago diagnostica France).16 Venous samples were
withdrawn after 8–10 h fasting and prior to receiving blood
transfusion. Plasma was separated immediately, INR, PTT
and D-dimer were done at once and the remaining plasma
was kept at 40 C until processed for sEPCR assay.
4.1. Statistical analysis
Results were statistically analyzed using SPSS version 16A.
Microsoft excel was used for graphing. All tests were two
tailed and a 0.05 level of signiﬁcance was used. Data were ana-
lyzed using the Kolmogorov. Smirnov test and Mann-Whitney
test.
5. Results
Group I included six males (40%) and nine females (60%) with
their age ranging from 19 to 59 years with a mean of
29.3 ± 12.2 years, while group II included four males
(26.67%) and 11 females (73.33%) with their age ranging from
18 to 38 years with a mean of 23.4 ± 5.6 years. History of epi-
staxis was found in eight patients (26.7%) and history of
thrombotic attacks (DVT and pulmonary embolism) in only
two patients (6.7%). Clinical examination revealed hepato-l.
Control Z P#
13.2 ± 0.8 6.657 0.000*
11.9–14.6
13.0
4.2 ± 0.6 4.411 0.000*
4.0–5.1
4.8
.9 84.6 ± 3.0 6.567 0.000*
78.2–88.9
85.2
6.9 ± 1.5 4.217 0.000*
4.3–9.1
6.9
193.9 318.8 ± 70.6 2.329 0.020*
3.0 198.0–423.0
321.0
9.1 ± 0.8 0.415 0.679
7.8–10.4
9.1
8.6 0.0 ± 0.0 7.114 0.000*
0.0 ± 0.0
0.0
11.2 42,000 ± 01.3 6.663 0.000*
45,000 24,000–81,600
48,000
Table 2 Hematological parameters in group I compared to group II.
Group I Group II Z P#
Hb (g/dl) Mean ± SD 7.8 ± 0.8 7.5 ± 1.3 1.268 0.217
Min–Max 6.3–9.5 5.7–10.8
Median 7.5 7.1
RBC (·1012 L1) Mean ± SD 3.1 ± 0.6 2.8 ± 0.7 6.628 0.351
Min–Max 2.3–4.6 1.9–3.9
Median 3.2 2.6
MCV (Fl) Mean ± SD 67.1 ± 7.1 68.9 ± 6.9 0.954 0.340
Min–Max 50.3–78.3 55.5–79.2
Median 68.9 70.8
WBC (·109 L1) Mean ± SD 9.8 ± 2.1 9.9 ± 3.7 0.394 0.693
Min–Max 6.4–13.4 5.3–19.2
Median 9.6 9.2
Platelets (·109 L1) Mean ± SD 561.5 ± 150.7 294.6 ± 130.4 3.859 0.000*
Min–Max 252.0–793.0 141.0–607.0
Median 532.0 298.0
MPV (Fl) Mean ± SD 9.6 ± 1.1 8.9 ± 1.2 1.619 0.106
Min–Max 7.5–11.1 7.1–11.4
Median 9.6 8.7
Normoblasts/100WBCs Mean ± SD 34.0 ± 52.5 9.8 ± 3.5 3.636 0.000*
Min–Max 5.0–222.0 4.0–16.0
Median 24.0 10.0
Absolute reticulocytic count Mean ± SD 142,600 ± 11.4 120,400 ± 01.9 0.851 0.412
Min–Max 62,100–345,000 47,500–237,900
Median 156,800 106,600
# P-value based on Mann–Whitney test.
* P< 0.05 (signiﬁcant).
Table 4 Coagulation parameters in group 1 compared to
group 2.
Group 1 Group 2 Z P
INR
Mean ± SD 1.3 ± 0.2 1.2 ± 0.2 0.664 0.507
Min–Max 1.1–1.8 1.0–1.5
Median 1.3 1.3
PTT (seconds)
Mean ± SD 42.1 ± 7.2 40.3 ± 6.1 0.602 0.547
Min–Max 32.1–61.2 33.0–52.0
Median 41.9 38.0
Table 3 Coagulation parameters in patients compared to
control.
Cases Control Z P
INR Mean ± SD 1.2 ± 0.2 1.04 ± 0.01 6.927 0.000*
Min–Max 1.0–1.8 1.0–1.1
Median 1.3 1.09
PTT
(seconds)
Mean ± SD 41.2 ± 6.6 35.1 ± 2.0 3.942 0.000*
Min–Max 32.1–61.2 32.1–38.2
Median 40.2 35.2
* P< 0.05 (signiﬁcant).
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group II. In the other group (group I) none of them had spleen
detected clinically due to previous splenectomy.
Table 1 shows the hematological data of patients compared
to the controls where the mean Hb concentration in patients
was 7.6 ± 1.1g/dl while in the control group it was 13.2 ±
0.8 g/dl. The mean WBC count was 9.8 ± 2.9 · 109 L1 in
the cases whereas it was 6.9 ± 1.5·109 L1 in the control
group. As regard the platelet counts, it had a mean of
428.1 ± 193.9 · 109 L1 in the patients group and a mean of
318.8 ± 70.6 · 109 L1 in the control group. Nucleated RBCs
were found in the peripheral blood of all the cases with a mean
of 21.9 ± 38.6/100WBCs while they were absent in the periph-
eral blood of the control group. The absolute reticulocytic
count ranged from 47,500 to 345,000 in the patients with a
mean of 130,500 ± 11.2 while it ranged from 24,000-81,000
in the controls with a mean of 42,000 ± 1.3. Statistical analysis
showed that there was statistical signiﬁcant difference between
patients and controls as regard Hb values, RBC counts, MCV,
WBC counts(P= 0.000), platelets counts (P= 0.020) as well
as normoblasts and reticulocytic counts (P= 0.000). On com-
paring the hematological parameters of group I and group II,
platelet counts had a mean of 561.5 ± 150.7 · 109 L1 in
group I which was signiﬁcantly higher than its mean values
in group II (294,6 ± 130.4 · 109 L1) (P= 0.000) as well as
the normoblasts count which ranged from 5.0 -222.0/
100WBCs with a mean of 34.0 ± 52.5 /100WBCs in group I
whereas it ranged from 4.0 – 16.0/100WBCs with a mean of
9.8 ± 3.5/100WBCs in group II and the difference was statis-
Figure 1 Correlation between sEPCR and WBC count.
286 M. Elgammal et al.tically signiﬁcant (P= 0.000) as shown in Table 2. Analysis of
variance showed statistically signiﬁcant difference between all
thalassemic patients and normal control (P= 0.000) as regard
the coagulation parameters as the mean INR was 1.2 ± 0.2 in
patients and was 1.04 ± 0.01 in controls. On comparing both
groups, the mean INR values in group I are higher than that of
group II but with no statistical signiﬁcant difference (Tables 3
and 4).
As regard sEPCR level, it was signiﬁcantly higher in
patients than control (P= 0.008) (Table 5). Although group
I had a higher mean level of plasma sEPCR compared to
group II, yet the difference was not statistically signiﬁcant
(P= 0.709) (Table 6). But still there was a signiﬁcant differ-
ence when each group was separately compared to the control
(P= 0.021 and 0.048, respectively) (Tables 7 and 8).
D-dimer test was negative in all the studied groups (data
not shown).Table 5 sEPCR level in patients compared to control.
sEPCR (ng/ml) Cases Control Z P
Mean ± SD 265.6 ± 255.1 106.3 ± 46.1 2.632 0.008*
Min–Max 38.7–1073.1 20.0–151.3
Median 157.4 129.6
* P< 0.05 (signiﬁcant).
Table 6 sEPCR level in group 1 compared to group 2.
sEPCR (ng/ml) Group 1 Group 2 Z P
Mean ± SD 309.9 ± 314.4 221.1 ± 177.9 0.373 0.709
Min–Max 38.7–1073.1 40.0–600.0
Median 160.0 144.7
Table 7 sEPCR level in group 1 compared to control.
sEPCR (ng/ml) Cases Control Z P
Mean ± SD 309.9 ± 314.5 106.3 ± 46.1 2.312 0.021*
Min–Max 38.7–1073.1 20.0–151.3
Median 160.0 129.6
* P< 0.05 (signiﬁcant).
Table 8 sEPCR level in group 2 compared to control.
sEPCR (ng/ml) Group 2 Control Z P
Mean ± SD 221.1 ± 177.9 106.3 ± 46.1 1.975 0.048*
Min–Max 40.0–600.0 20.0–151.3
Median 144.7 129.6
* P< 0.05 (signiﬁcant).
Figure 2 Correlation between sEPCR and platelet counts.5.1. Correlation studies
A signiﬁcant positive correlation was observed between sEP-
CR and total leukocytic count (P= 0.015) as well as platelet
count (P= 0.020) (Figs. 1 and 2), respectively. But no correla-
tion was found between sEPCR and age or sex.
6. Discussion
Profound hemostatic derangements are observed in patients
with b-thalassemia. The chronic hypercoagulable state in these
patients is multifactorial, and endothelial dysfunction has
emerged as a causal factor in this hypercoagulability.17,18
In the present study, sEPCR was signiﬁcantly higher in
thalassemic patients than the control (P= 0.008). This may
reﬂect a state of hypercoagulability, possibly induced by endo-
thelial injury secondary to oxidative stress or platelet activa-
tion with subsequent release of procoagulant proteins. This
is evidenced by the positive correlation with platelet count. A
higher platelet count was observed in patients compared to
the control (P= 0.02) especially in splenectomized patients
(P= 0.000).
Setiabudy et al.19 found higher platelet count in splenec-
tomized versus non-splenectomized group. The hazards of
thrombosis especially following splenectomy may range from
portal vein thrombosis to pulmonary embolism and deep vein
thrombosis.19–21 As platelets play an important role in the
pathogenesis of thrombosis, autopsy based studies by
Fucharoen and his colleagues22 in a large number of thalasse-
mic patients documented striking pulmonary artery occlusions
as well as another study done by Taher et al. had estimated the
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patients.23
In agreement with our ﬁndings, Mohren et al.24 and Van’t
Riet et al.25 also reported thromboembolic complications in
splenectomized patients.
On the other hand, a higher mean platelet volume (MPV)
was found in group I compared to group II reﬂecting a state
of platelet hyperactivity. The enhanced platelet function added
to the higher platelet number constitutes a double risk of
hypercoagulability in splenectomized patients. These ﬁndings
coincide with those of Setiabudy et al.19 and they highlight
the role of the platelets in inducing endothelial damage which
is followed by enhanced production of sEPCR.
In the present study, D-dimer test was negative in all stud-
ied groups even in patients with the highest plasma levels of s
EPCR which conﬁrmed the study of Setiabudy et al.19 who re-
ported normal D-dimer in all their studied thalassemic
patients.
In addition, we demonstrated a positive correlation be-
tween sEPCR and total leukocytic count (TLC). This was
attributed to the fact that the activated neutrophils and mono-
cytes in thalassemic patients release their proteolytic enzymes
with production of free oxygen radicals as well as inﬂamma-
tory cytokines that damage the endothelium which eventually
produce EPCR degradation into its soluble form. This agrees
with Boossma et al.26 who studied plasma levels of sEPCR
in cases of Wagener granulomatosis and found a positive cor-
relation between their levels and disease activity.
As regards the INR and PTT, they were found prolonged in
86.7% and 83.3% of the patients and were statistically signif-
icant compared to the control (P= 0.000, P= 0.000), respec-
tively. Similarly, Naithani et al.27 found prolongation of INR
in 40.7% and PTT in 46.3% of their patients.
Epistaxis was found in 26%of our patients in agreement with
the ﬁndings of Naithani et al.27 study, in which sixteen out of the
studied 54 thalassemic patients had bleeding manifestations. Al-
tered liver functions, and poor chelation might be risk factors
for altered hemostasis in these patients. In their study, they re-
ported low protein C, protein S and antithrombin III as well
as Eldor et al.17 and Sivgar et al.28 who found signiﬁcantly de-
creased levels of these anticoagulant proteins which were ex-
plained by combined consumption and liver dysfunction.
In the present study, no correlation was found between
sEPCR and age as our patients were adults. Recently, Orhon
et al.29 reported higher levels in healthy children compared
to healthy adults. Similarly, Kuraswa et al.28 found a negative
correlation between sEPCE level and age of the pediatric
group, but they failed to establish this negative correlation in
the adult group. The higher level of sEPCR in healthy children
suggests a regulatory mechanism for the protein C system over
the ﬁrst years of life, as the highest level of sEPCR in their
study, was found in the ﬁrst year of life.28
As regards gender, we could not establish a relation be-
tween gender and sEPCR. On the contrary, Orhon et al.29
found higher levels in males and were attributed to environ-
mental factors including smoking.
In conclusion, our study documented increased sEPCR in
patients with b-thalassemia which could be implicated in the
hemostatic derangement in these patients. Hence, close moni-
toring of the hemostatic system in thalassemia is highly recom-
mended especially with increasing age and in splenectomizedpatients to avoid the morbid complications of hypercoagula-
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